Fig. 3From: Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancerHigher levels of post-treatment antibodies are associated with improved disease-free survival. Kaplan-Meier curve showing disease-free survival (DFS) in all patients (N = 50) with antibody changes of ≥0.2 RI units (inclusive of all arms) compared with patients that did not experience increased antibodiesBack to article page